Pages that link to "Q37006876"
Jump to navigation
Jump to search
The following pages link to MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr (Q37006876):
Displaying 50 items.
- MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management (Q26785379) (← links)
- Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review (Q27304386) (← links)
- Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma (Q27853399) (← links)
- Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies (Q28067817) (← links)
- Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update (Q28078869) (← links)
- Lymphoma: turning biology into cures (Q30240069) (← links)
- Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research (Q30275206) (← links)
- Novel prognostic genes of diffuse large B-cell lymphoma revealed by survival analysis of gene expression data (Q31028064) (← links)
- Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial (Q33431267) (← links)
- Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study (Q33441858) (← links)
- Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. (Q33601156) (← links)
- Role of MYC in B Cell Lymphomagenesis. (Q33608499) (← links)
- Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review (Q33670880) (← links)
- Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma (Q33700531) (← links)
- Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives (Q33729711) (← links)
- B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study (Q33809728) (← links)
- Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. (Q33846801) (← links)
- MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified (Q34000188) (← links)
- Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma (Q34104112) (← links)
- Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma (Q34287747) (← links)
- Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms (Q34617849) (← links)
- MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system (Q34640550) (← links)
- Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. (Q34882773) (← links)
- Immunohistochemistry for myc predicts survival in colorectal cancer (Q35087649) (← links)
- Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma (Q35128216) (← links)
- Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP (Q35145270) (← links)
- Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis (Q35419876) (← links)
- Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma (Q35740025) (← links)
- Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma (Q35742364) (← links)
- Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. (Q35742367) (← links)
- Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. (Q35755485) (← links)
- Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. (Q35880791) (← links)
- Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 (Q35920657) (← links)
- Epstein-Barr virus oncoprotein super-enhancers control B cell growth (Q35963272) (← links)
- Genetic lesions in diffuse large B-cell lymphomas (Q35974341) (← links)
- Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies (Q36011142) (← links)
- MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. (Q36048764) (← links)
- Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma (Q36093288) (← links)
- Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. (Q36192439) (← links)
- MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma (Q36210875) (← links)
- Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review (Q36302961) (← links)
- Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma (Q36467468) (← links)
- p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function (Q36681461) (← links)
- Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. (Q36771814) (← links)
- Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature (Q36799405) (← links)
- The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. (Q37024999) (← links)
- Clinical Significance of "Double-hit" and "Double-protein" expression in Primary Gastric B-cell Lymphomas (Q37067986) (← links)
- Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma (Q37100081) (← links)
- Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. (Q37109671) (← links)
- MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma (Q37142412) (← links)